Bird Flu Claims First U.S. Life in Louisiana

Seeking Alpha06:22

FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development

Seeking Alpha01:52

Can 2025 Spark a Turnaround for S&P 500 Materials Sector After Negative Annual Returns?

Seeking Alpha00:14

Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study

BenzingaJan 6 21:52

The S&P 500's 10 Worst Performing Stocks in 2023 Fell Again in 2024

Seeking AlphaJan 4 01:42

Insurance is not covered, supply shortages, rampant generic drugs, slow new drug development, and new weight-loss medications still face challenges.

New GLP-1 weight loss drugs are not only changing the lives of obese populations but also creating billions of dollars in revenue for pharmaceutical companies like Eli Lilly and Co and Novo-Nordisk A/S. However, analysis indicates that weight loss drugs currently face some challenges in the USA: there is the risk of insurance companies refusing to pay, and ongoing supply shortages have created opportunities for lower-priced generic drugs. Additionally, it remains uncertain whether pharmaceutical companies can truly develop better weight loss medications and what the new U.S. government's attitude toward weight loss drugs will be.

wallstreetcnJan 3 00:17